Adenosine receptors and their modulators.

The identification and characterization of adenosine receptors and the development of potent, receptor subtype-selective agonists and antagonists has been an active area of research for the past 20 years. Major recent advances in the field have been the cloning of several adenosine receptor subtypes of different species, including the discovery of a new subtype, designated A3, the discovery and development of new agonists and antagonists, particularly those with selectivity for the A2a adenosine receptor, the characterization of signal transduction pathways, and the development of agents which act indirectly on the adenosine receptor system. The present article focusses on aspects of pharmaceutical/medicinal chemistry related to adenosine receptors.

[1]  N. Peet,et al.  Conformationally restrained, chiral (phenylisopropyl)amino-substituted pyrazolo[3,4-d]pyrimidines and purines with selectivity for adenosine A1 and A2 receptors. , 1992, Journal of medicinal chemistry.

[2]  J. Dumont,et al.  Cloning and functional characterization of a human A1 adenosine receptor. , 1992, Biochemical and biophysical research communications.

[3]  J. Fergus,et al.  Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. , 1990, Molecular pharmacology.

[4]  B. K. Trivedi,et al.  N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor. , 1988, Journal of Medicinal Chemistry.

[5]  J. Linden Adenosine deaminase for removing adenosine: how much is enough? , 1989, Trends in pharmacological sciences.

[6]  H. W. Hamilton,et al.  Synthesis and structure-activity relationships of pyrazolo[4,3-d]pyrimidin-7-ones as adenosine receptor antagonists. , 1987, Journal of medicinal chemistry.

[7]  A. IJzerman,et al.  1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. , 1991, Journal of medicinal chemistry.

[8]  K. Jacobson,et al.  Autoradiographic localization of mouse brain adenosine receptors with an antagonist ([3H]xanthine amine congener) ligand probe , 1988, Neuroscience Letters.

[9]  R. F. Bruns Structure Activity Relationships for Adenosine Antagonists , 1990 .

[10]  A. Bridges,et al.  N6-bicycloalkyladenosines with unusually high potency and selectivity for the adenosine A1 receptor. , 1989, Journal of medicinal chemistry.

[11]  J. Daly,et al.  7-Deaza-9-phenyladenines. A new class of adenosine receptor antagonists. , 1988, Biochemical pharmacology.

[12]  B. Cronstein,et al.  Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Sergi Ferré,et al.  Antagonistic A2a/D2 receptor interactions in the striatum as a basis for adenosine/dopamine interactions in the central nervous system , 1993 .

[14]  C. Müller,et al.  Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors. , 1993, Journal of medicinal chemistry.

[15]  L. Miller,et al.  High selectivity of novel isoguanosine analogues for the adenosine A1 receptor , 1991 .

[16]  K. Jacobson,et al.  Adenosine receptor prodrugs: towards kidney-selective dialkylxanthines. , 1989, The Journal of pharmacology and experimental therapeutics.

[17]  A S Clanachan Antagonism of presynaptic adenosine receptors by theophylline 9-beta-D-riboside and 8-phenyltheophylline. , 1981, Canadian journal of physiology and pharmacology.

[18]  M. Williams,et al.  Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential. , 1992, Journal of medicinal chemistry.

[19]  R. Olsson,et al.  Coronary vasoactivity of novel N6-substituted adenosines , 1991 .

[20]  D. Mckenna,et al.  (+-)-N6-endonorbornan-2-yl-9-methyladenine (N-0861) and its enantiomers: selective antagonists of A1-adenosine receptors in guinea pig isolated atria. , 1993, Journal of Pharmacology and Experimental Therapeutics.

[21]  R F Bruns,et al.  Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. , 1980, Canadian journal of physiology and pharmacology.

[22]  J. Daly,et al.  Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. , 1986, Journal of medicinal chemistry.

[23]  G. Ghai,et al.  Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines. , 1991, Journal of medicinal chemistry.

[24]  R. Quinn,et al.  A computer generated model of adenosine receptors rationalising binding and selectivity of receptor ligands , 1991 .

[25]  A. Fasbender,et al.  C-2 functionalized N6-cyclosubstituted adenosines : highly selective agonists for the adenosine A1 receptor , 1993 .

[26]  A. Paterson,et al.  Potencies of mioflazine and its derivatives as inhibitors of adenosine transport in isolated erythrocytes from different species , 1990, The Journal of pharmacy and pharmacology.

[27]  J. Deckert,et al.  Adenosine uptake site heterogeneity in the mammalian CNS? Uptake inhibitors as probes and potential neuropharmaceuticals. , 1988, Life sciences.

[28]  R. G. Browne,et al.  4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants. , 1990, Journal of medicinal chemistry.

[29]  U. Schwabe,et al.  Characterization of Membrane‐Bound and Solubilized High‐Affinity Binding Sites for 5′‐N‐Ethylcarboxamido[3H]adenosine from Bovine Cerebral Cortex , 1993, Journal of neurochemistry.

[30]  R. Olsson,et al.  Use of Structure-Activity Relationships in the Study of Adenosine Receptors , 1985 .

[31]  G. Sutherland,et al.  Binding of the Adenosine A2 Receptor Ligand [3H]CGS 21680 to Human and Rat Brain: Evidence for Multiple Affinity Sites , 1990, Journal of neurochemistry.

[32]  K. Jacobson,et al.  A new high affinity, iodinated adenosine receptor antagonist as a radioligand/photoaffinity crosslinking probe. , 1987, Molecular pharmacology.

[33]  G. Stiles A1 Adenosine Receptor‐G Protein Coupling in Bovine Brain Membranes: Effects of Guanine Nucleotides, Salt, and Solubilization , 1988, Journal of neurochemistry.

[34]  K. Jacobson,et al.  [3H]xanthine amine congener of 1,3-dipropyl-8-phenylxanthine: an antagonist radioligand for adenosine receptors. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[35]  H. van Belle,et al.  Nucleoside transport inhibition for cardioprotection: New perspectives for the clinic , 1993 .

[36]  M. Williams,et al.  Adenosine A1 receptors in mammalian brain: Species differences in their interactions with agonists and antagonists , 1986 .

[37]  J. Daly,et al.  Caffeine and theophylline analogues: correlation of behavioral effects with activity as adenosine receptor antagonists and as phosphodiesterase inhibitors. , 1988, Life sciences.

[38]  S Schiffmann,et al.  RDC8 codes for an adenosine A2 receptor with physiological constitutive activity. , 1990, Biochemical and biophysical research communications.

[39]  K. Klotz,et al.  2',3'-Dideoxy-N6-cyclohexyladenosine: an adenosine derivative with antagonist properties at adenosine receptors. , 1988, European journal of pharmacology.

[40]  K. Jacobson,et al.  [3H]XAC (xanthine amine congener) is a radioligand for A2-adenosine receptors in rabbit striatum , 1991, Neurochemistry International.

[41]  J. Fergus,et al.  PD 115,199: An antagonist ligand for adenosine A2 receptors , 1986, Naunyn-Schmiedeberg's Archives of Pharmacology.

[42]  W. Schiemann,et al.  On the ability of endogenous adenosine to regulate purine nucleoside receptor binding of antagonists in smooth muscle membranes. , 1990, Journal of Pharmacology and Experimental Therapeutics.

[43]  G. Ghai,et al.  CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity. , 1989, Journal of Pharmacology and Experimental Therapeutics.

[44]  S. Snyder,et al.  Adenosine receptors in brain membranes: binding of N6-cyclohexyl[3H]adenosine and 1,3-diethyl-8-[3H]phenylxanthine. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[45]  U. Schwabe,et al.  Characterization of adenosine receptors in rat brain by (−)[3H]N6-phenylisopropyladenosine , 1980, Naunyn-Schmiedeberg's Archives of Pharmacology.

[46]  B. Weeks,et al.  Species differences in high‐affinity adenosine A2 binding sites in striatal membranes from mammalian brain , 1988 .

[47]  J. Daly,et al.  Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions. , 1989, Journal of medicinal chemistry.

[48]  R. Quinn,et al.  An explanation of the substituent effect of 1,3,8-trisubstituted xanthines on adenosine A1/A2 affinity. , 1992 .

[49]  K. Jacobson,et al.  Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors. , 1989, Journal of medicinal chemistry.

[50]  R. F. Bruns,et al.  Adenosine antagonism by purines, pteridines and benzopteridines in human fibroblasts. , 1981, Biochemical pharmacology.

[51]  K. Jacobson,et al.  8-Substituted xanthines as antagonists at A1- and A2-adenosine receptors. , 1988, Biochemical pharmacology.

[52]  J. Fozard,et al.  Adenosine A3 receptors 1 mediate hypotension in the angiotensin II‐supported circulation of the pithed rat , 1993, British journal of pharmacology.

[53]  C. Müller,et al.  Stimulation of calcium release by caffeine analogs in pheochromocytoma cells. , 1993, Biochemical pharmacology.

[54]  M. Ueeda,et al.  2-(N'-alkylidenehydrazino)adenosines: potent and selective coronary vasodilators. , 1992, Journal of medicinal chemistry.

[55]  G Vassart,et al.  Selective amplification and cloning of four new members of the G protein-coupled receptor family. , 1989, Science.

[56]  A. Matsuda,et al.  Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity. , 1992, Journal of medicinal chemistry.

[57]  D. Ukena,et al.  [125I] N6-p-hydroxyphenylisopropyladenosine, a new ligand for Ri adenosine receptors , 1982, Naunyn-Schmiedeberg's Archives of Pharmacology.

[58]  A. Wauquier,et al.  The nucleoside-transport inhibitor soluflazine (R 64 719) increases the effects of adenosine in the guinea-pig hippocampal slice and is antagonized by adenosine deaminase. , 1987, European journal of pharmacology.

[59]  R. Midgett,et al.  Adenosine deaminase inhibitors. Synthesis and biological evaluation of C1' and nor-C1' derivatives of (+)-erythro-9-(2(S)-hydroxy-3(R)-nonyl)adenine. , 1992, Journal of medicinal chemistry.

[60]  H. W. Hamilton,et al.  Synthesis of xanthines as adenosine antagonists, a practical quantitative structure-activity relationship application. , 1985, Journal of medicinal chemistry.

[61]  A. Matsuda,et al.  Nucleosides and nucleotides. 107. 2-(cycloalkylalkynyl)adenosines: adenosine A2 receptor agonists with potent antihypertensive effects. , 1992, Journal of medicinal chemistry.

[62]  A. IJzerman,et al.  Inhibition of nucleoside transport by a new series of compounds related to lidoflazine and mioflazine. , 1989, European journal of pharmacology.

[63]  J. Fergus,et al.  Solubilities of Adenosine Antagonists Determined by Radioreceptor Assay , 1989, The Journal of pharmacy and pharmacology.

[64]  S. Rivkees,et al.  Molecular cloning and expression of the cDNA for a novel A2-adenosine receptor subtype. , 1992, Molecular endocrinology.

[65]  F. Gusovsky,et al.  Frog secretions and hunting magic in the upper Amazon: identification of a peptide that interacts with an adenosine receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[66]  G D Schuler,et al.  A workbench for multiple alignment construction and analysis , 1991, Proteins.

[67]  G. Cristalli,et al.  Adenosine deaminase inhibitors: synthesis and structure-activity relationships of imidazole analogues of erythro-9-(2-hydroxy-3-nonyl)adenine. , 1991, Journal of medicinal chemistry.

[68]  A. IJzerman,et al.  A steric and electrostatic comparison of three models for the agonist/antagonist binding site on the adenosine A1 receptor. , 1992, Journal of medicinal chemistry.

[69]  B. K. Trivedi,et al.  [1,2,4]Triazolo[4,3-a]quinoxalin-4-amines: a new class of A1 receptor selective adenosine antagonists. , 1988, Journal of medicinal chemistry.

[70]  J. Ribeiro,et al.  Adenosine receptors and calcium: Basis for proposing a third (A3) adenosine receptor , 1986, Progress in Neurobiology.

[71]  R. Thompson,et al.  2-(N'-aralkylidenehydrazino)adenosines: potent and selective coronary vasodilators. , 1992, Journal of medicinal chemistry.

[72]  B. K. Trivedi,et al.  C2,N6-disubstituted adenosines: synthesis and structure-activity relationships. , 1989, Journal of medicinal chemistry.

[73]  R. A. Johnson,et al.  Potent adenosine receptor antagonists that are selective for the A1 receptor subtype. , 1987, Molecular pharmacology.

[74]  S. Rivkees,et al.  Molecular cloning and characterization of a rat A1-adenosine receptor that is widely expressed in brain and spinal cord. , 1991, Molecular endocrinology.

[75]  A. Paoletti,et al.  Prolonged in vitro exposure of rat brain slices to adenosine analogues: selective desensitization of adenosine A1 but not A2 receptors. , 1992, European journal of pharmacology.

[76]  K. Jacobson,et al.  Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[77]  J. Uzawa,et al.  Restriction of the C6N6 bond rotation of adenosine compounds investigated by 1H‐ and 15N‐NMR spectra , 1988 .

[78]  M. Parmentier,et al.  The orphan receptor cDNA RDC7 encodes an A1 adenosine receptor. , 1991, The EMBO journal.

[79]  J. Linden,et al.  125I-labeled 8-phenylxanthine derivatives: antagonist radioligands for adenosine A1 receptors. , 1988, Journal of medicinal chemistry.

[80]  T. Heffner,et al.  Ribose-modified adenosine analogues as adenosine receptor agonists. , 1986, Journal of medicinal chemistry.

[81]  N P Peet,et al.  A novel synthesis of xanthines: support for a new binding mode for xanthines with respect to adenosine at adenosine receptors. , 1990, Journal of medicinal chemistry.

[82]  K. Jacobson,et al.  Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. , 1993, Journal of medicinal chemistry.

[83]  J. Shimada,et al.  8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors. , 1992, Journal of medicinal chemistry.

[84]  R. Henderson,et al.  Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. , 1990, Journal of molecular biology.

[85]  W. Padgett,et al.  Interaction of Anticonvulsant Drugs with Adenosine Receptors in the Central Nervous System , 1984, Epilepsia.

[86]  S. Schiffmann,et al.  Adenosine A2a receptor expression in striatal neurons: Implications for basal ganglia pathophysiology , 1993 .

[87]  A. Matsuda,et al.  Nucleosides and nucleotides. 103. 2-Alkynyladenosines: a novel class of selective adenosine A2 receptor agonists with potent antihypertensive effects. , 1992, Journal of medicinal chemistry.

[88]  R. North,et al.  Functional expression of adenosine A2b receptor in Xenopus oocytes. , 1993, Molecular pharmacology.

[89]  J. Daly,et al.  Imidazodiazepinediones: a new class of adenosine receptor antagonists. , 1990, Journal of Medicinal Chemistry.

[90]  G. Lu,et al.  Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. , 1986, Molecular pharmacology.

[91]  A. Ménez,et al.  Molecular cloning of a cDNA encoding the precursor of adenoregulin from frog skin. Relationships with the vertebrate defensive peptides, dermaseptins. , 1993, Biochemical and biophysical research communications.

[92]  J. Daly,et al.  3,7-Dimethyl-1-propargylxanthine: a potent and selective in vivo antagonist of adenosine analogs. , 1988, Life sciences.

[93]  G. Stiles Adenosine receptors: structure, function and regulation , 1986 .

[94]  K. Klotz,et al.  2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors. , 1992, Journal of medicinal chemistry.

[95]  G. Ghai,et al.  2-(Arylalkylamino)adenosin-5'-uronamides: a new class of highly selective adenosine A2 receptor ligands. , 1990, Journal of medicinal chemistry.

[96]  K. Jacobson,et al.  Binary drugs: conjugates of purines and a peptide that bind to both adenosine and substance P receptors. , 1987, Journal of medicinal chemistry.

[97]  K. Jacobson,et al.  Molecular probes for extracellular adenosine receptors. , 1987, Biochemical pharmacology.

[98]  K. Kubo,et al.  Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure. , 1992, Journal of medicinal chemistry.

[99]  A. Galione Ca(2+)-induced Ca2+ release and its modulation by cyclic ADP-ribose. , 1992, Trends in pharmacological sciences.

[100]  J. Daly,et al.  Structure-activity relationships for N6-substituted adenosines at a brain A1-adenosine receptor with a comparison to an A2-adenosine receptor regulating coronary blood flow. , 1986, Biochemical pharmacology.

[101]  T. Hasegawa,et al.  Effects of alkyl substitutions of xanthine skeleton on bronchodilation. , 1992, Journal of medicinal chemistry.

[102]  T. Heffner,et al.  N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity. , 1987, Journal of medicinal chemistry.

[103]  K. Jacobson,et al.  Novel therapeutics acting via purine receptors. , 1991, Biochemical pharmacology.

[104]  J. Fergus,et al.  Structure-activity relationships for enhancement of adenosine A1 receptor binding by 2-amino-3-benzoylthiophenes. , 1990, Molecular pharmacology.

[105]  M. Ueeda,et al.  2-Phenylethoxy-9-methyladenine: an adenosine receptor antagonist that discriminates between A2 adenosine receptors in the aorta and the coronary vessels from the guinea pig. , 1993, The Journal of pharmacology and experimental therapeutics.

[106]  K. Jacobson,et al.  A2A adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: characterization with radioligand binding and by activation of adenylate cyclase. , 1992, Molecular pharmacology.

[107]  J. Linden,et al.  125I-BW-A844U, an antagonist radioligand with high affinity and selectivity for adenosine A1 receptors, and 125I-azido-BW-A844U, a photoaffinity label. , 1988, Molecular pharmacology.

[108]  A Sattin,et al.  The effect of adenosine and adenine nucleotides on the cyclic adenosine 3', 5'-phosphate content of guinea pig cerebral cortex slices. , 1970, Molecular pharmacology.

[109]  W. Meyerhof,et al.  Molecular cloning of a novel putative G‐protein coupled receptor expressed during rat spermiogenesis , 1991, FEBS letters.

[110]  S. Klumpp,et al.  Pyrrolo[2,3-d]pyrimidines as inhibitors of cAMP-phosphodiesterase. Structure-activity relationship. , 1989, Biochemical pharmacology.

[111]  G. Ghai,et al.  Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists. , 1988, Journal of medicinal chemistry.

[112]  K. Jacobson,et al.  Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists. , 1992, Journal of medicinal chemistry.

[113]  N. Wiklund,et al.  Subclassification of Neuronal Adenosine Receptors , 1990 .

[114]  C. Müller,et al.  Methylxanthines block antigen-induced responses in RBL-2H3 cells independently of adenosine receptors or cyclic AMP: evidence for inhibition of antigen binding to IgE. , 1991, The Journal of pharmacology and experimental therapeutics.

[115]  C. Müller,et al.  Caffeine analogs: structure-activity relationships at adenosine receptors. , 1991, Pharmacology.

[116]  S. Hurt,et al.  [3H]2-phenylaminoadenosine ([3H]CV 1808) labels a novel adenosine receptor in rat brain. , 1992, The Journal of pharmacology and experimental therapeutics.

[117]  H. Baer,et al.  5'-Deoxy-5'-methylthioadenosine: a nucleoside which differentiates between adenosine receptor types. , 1988, Biochemical pharmacology.

[118]  R. Quinn,et al.  The three binding domain model of adenosine receptors: molecular modeling aspects. , 1992, Journal of medicinal chemistry.

[119]  K. Jacobson,et al.  Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors. , 1993, Journal of medicinal chemistry.

[120]  J. Baldwin The probable arrangement of the helices in G protein‐coupled receptors. , 1993, The EMBO journal.

[121]  C. J. Blankley,et al.  N6-substituted adenosine receptor agonists: potential antihypertensive agents. , 1991, Journal of medicinal chemistry.

[122]  A. Tucker,et al.  Cloning and expression of a bovine adenosine A1 receptor cDNA , 1992, FEBS letters.

[123]  R. Wolfenden,et al.  Transition-state discrimination by adenosine deaminase from Aspergillus oryzae. , 1993, Biochimica et biophysica acta.

[124]  K. Jacobson,et al.  The A2 adenosine receptor: guanine nucleotide modulation of agonist binding is enhanced by proteolysis. , 1991, Molecular pharmacology.

[125]  S. Krawczyk,et al.  Rapid communication: Inhibition of adenosine deaminase by azapurine ribonucleosides , 1992 .

[126]  S. Snyder,et al.  Adenosine as a neuromodulator. , 1985, Annual review of neuroscience.

[127]  F. Kuhn,et al.  Selective A1-Antagonists for Treatment of Cognitive Deficits , 1991 .

[128]  J. Pearson,et al.  The control of adenosine concentration in polymorphonuclear leucocytes, cultured heart cells and isolated perfused heart from the rat. , 1983, The Biochemical journal.

[129]  R. Agarwal Inhibitors of adenosine deaminase. , 1982, Pharmacology & therapeutics.

[130]  R. Vestal,et al.  Cardiac functional responses to adenosine by PD 81,723, an allosteric enhancer of the adenosine A1 receptor. , 1993, The American journal of physiology.

[131]  T J Furlong,et al.  Molecular characterization of a human brain adenosine A2 receptor. , 1992, Brain research. Molecular brain research.

[132]  K. Jacobson,et al.  Adenosine A1 receptor and ligand molecular modeling , 1993 .

[133]  J. Daly,et al.  N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. , 1991, Journal of medicinal chemistry.

[134]  L. Arroyo,et al.  2-Alkoxyadenosines: potent and selective agonists at the coronary artery A2 adenosine receptor. , 1991, Journal of medicinal chemistry.

[135]  A. Szent-Györgyi,et al.  The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart 1 , 1929, The Journal of physiology.

[136]  Zhenqiang Yang,et al.  Regiospecific introduction of carbon-3 formyl group to 2,5-dialkyl-7-methoxy-benzo[b] furans : Synthesis of potential ligands for adenosine A1 receptors , 1992 .

[137]  K. Klotz,et al.  Barbiturates Are Selective Antagonists at A1 Adenosine Receptors , 1985, Journal of neurochemistry.

[138]  A. IJzerman,et al.  Mapping the N6-region of the adenosine A1 receptor with computer graphics. , 1989, European journal of pharmacology.

[139]  J. N. Wells,et al.  Structure-activity relationships of 8-cycloalkyl-1,3-dipropylxanthines as antagonists of adenosine receptors. , 1990, Journal of medicinal chemistry.

[140]  W. Moos,et al.  N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists. , 1985, Journal of medicinal chemistry.

[141]  K. Jacobson,et al.  A functionalized congener approach to adenosine receptor antagonists: amino acid conjugates of 1,3-dipropylxanthine. , 1986, Molecular pharmacology.

[142]  G. Lu,et al.  Adenosine Receptor Subtypes: Binding Studies , 1987 .

[143]  J. Daly,et al.  Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors. , 1991, Journal of medicinal chemistry.

[144]  K. Mullane,et al.  Acadesine: Prototype adenosine regulating agent for treating myocardial ischemia‐reperfusion injury , 1993 .

[145]  J. Daly,et al.  Agonist activity of 2- and 5'-substituted adenosine analogs and their N6-cycloalkyl derivatives at A1- and A2-adenosine receptors coupled to adenylate cyclase. , 1992, Biochemical pharmacology.

[146]  K. Klotz,et al.  Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives. , 1988, Journal of medicinal chemistry.

[147]  E. M. Adler,et al.  Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. , 1992, Brain research. Molecular brain research.

[148]  J. Daly Adenosine receptors: targets for future drugs. , 1982, Journal of medicinal chemistry.

[149]  Zhenqiang Yang,et al.  Compounds from Danshen. Part 7. Regioselective introduction of carbon-3 substituents to 5-alkyl-7-methoxy-2-phenylbenzo[b]furans: synthesis of a novel adenosine A1 receptor ligand and its derivatives , 1992 .

[150]  K. Jacobson,et al.  Functionalized congeners of 1,3-dialkylxanthines: preparation of analogues with high affinity for adenosine receptors. , 1985, Journal of medicinal chemistry.

[151]  G. Cristalli,et al.  Adenosine and 2-Chloroadenosine Deaza-Analogues as Adenosine Receptor Agonists1 , 1985 .

[152]  M. Williams,et al.  [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. , 1989, The Journal of pharmacology and experimental therapeutics.

[153]  G. Stiles,et al.  Reciprocal modulation of agonist and antagonist binding to A1 adenosine receptors by guanine nucleotides is mediated via a pertussis toxin-sensitive G protein. , 1988, The Journal of pharmacology and experimental therapeutics.

[154]  B. Hamprecht,et al.  Nomenclature of adenosine receptors , 1985 .

[155]  J. Miller,et al.  In vitro and in vivo pharmacological characterization of N6-cyclopentyl-9-methyladenine (N-0840): a selective, orally active A1 adenosine receptor antagonist. , 1993, The Journal of pharmacology and experimental therapeutics.

[156]  K. Kubo,et al.  8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: a potent and selective adenosine A1 antagonist with renal protective and diuretic activities. , 1991, Journal of medicinal chemistry.

[157]  Adriaan P. IJzerman,et al.  Xanthine-7-Ribosides as Adenosine Al Receptor Antagonists: Further Evidence for Adenosine's Anti Mode of Binding , 1990 .

[158]  S E Ealick,et al.  Application of crystallographic and modeling methods in the design of purine nucleoside phosphorylase inhibitors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[159]  Zhenqiang Yang,et al.  Naturally occurring benzofuran: isolation, structure elucidation and total synthesis of 5-(3-hydroxypropyl)-7-methoxy-2-(3′-methoxy-4′-hydroxyphenyl)-3-benzo[b]furancarbaldehyde, a novel adenosine A1 receptor ligand isolated from salvia miltiorrhiza bunge (danshen) , 1991 .

[160]  K. Jacobson,et al.  Adenosine analogs with covalently attached lipids have enhanced potency at A1‐adenosine receptors , 1987, FEBS letters.

[161]  F Suzuki,et al.  (E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists. , 1992, Journal of medicinal chemistry.

[162]  H. V. van Vlijmen,et al.  A model for the antagonist binding site on the adenosine A1 receptor, based on steric, electrostatic, and hydrophobic properties. , 1990, Journal of medicinal chemistry.

[163]  G. Stiles,et al.  Characterization of the A1 Adenosine Receptor‐Adenylate Cyclase System of Cerebral Cortex Using an Agonist Photoaffinity Ligand , 1986, Journal of neurochemistry.

[164]  J. Daly,et al.  1,3-Dialkyl-8-(p-sulfophenyl)xanthines: potent water-soluble antagonists for A1- and A2-adenosine receptors. , 1985, Journal of medicinal chemistry.

[165]  M. Williams,et al.  Evaluation of the binding of the A-1 selective adenosine radioligand, cyclopentyladenosine (CPA), to rat brain tissue , 1986, Naunyn-Schmiedeberg's Archives of Pharmacology.

[166]  K. Jacobson,et al.  Non-xanthine heterocycles: activity as antagonists of A1- and A2-adenosine receptors. , 1988, Biochemical pharmacology.

[167]  J. Shine,et al.  Molecular cloning and expression of an adenosine A2b receptor from human brain. , 1992, Biochemical and biophysical research communications.

[168]  J. Daly,et al.  Definition of subclasses of adenosine receptors associated with adenylate cyclase: interaction of adenosine analogs with inhibitory A1 receptors and stimulatory A2 receptors. , 1987, Canadian journal of physiology and pharmacology.

[169]  H. Simmonds,et al.  Purines: Basic and Clinical Aspects , 1991, Springer Netherlands.

[170]  T. Hasegawa,et al.  Bronchodilator activity of xanthine derivatives substituted with functional groups at the 1- or 7-position. , 1993, Journal of Medicinal Chemistry.

[171]  J Hoflack,et al.  Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. , 1991, Molecular pharmacology.

[172]  J. Daly,et al.  8-Aryl-and 8-cycloalkyl-1,3-dipropylxanthines: further potent and selective antagonists for A1-adenosine receptors. , 1988, Journal of medicinal chemistry.

[173]  C. Gerfen,et al.  Cloning and expression of an A1 adenosine receptor from rat brain. , 1991, Molecular pharmacology.

[174]  Adriaan P. IJzerman,et al.  Mapping the xanthine C8-region of the adenosine A1 receptor with computer graphics☆ , 1991 .

[175]  Y. Chern,et al.  Molecular cloning of a novel adenosine receptor gene from rat brain. , 1992, Biochemical and biophysical research communications.

[176]  J. Daly,et al.  Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors. , 1993, Pharmacology.

[177]  B. F. Becker,et al.  Topics and Perspectives in Adenosine Research , 1987, Springer Berlin Heidelberg.

[178]  I. Fox,et al.  Soluble and membrane-associated human low-affinity adenosine binding protein (adenotin): properties and homology with mammalian and avian stress proteins. , 1990, Biochemistry.

[179]  R. A. Johnson,et al.  Irreversible inactivation of adenylyl cyclase by the "P"-site agonist 2',5'-dideoxy-,3'-p-fluorosulfonylbenzoyl adenosine. , 1990, The Journal of biological chemistry.

[180]  J Hoflack,et al.  Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors. , 1992, Journal of medicinal chemistry.

[181]  K. Jacobson,et al.  Species differences in structure‐activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors , 1986, FEBS letters.

[182]  A. Bridges,et al.  N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor. , 1988, Journal of medicinal chemistry.

[183]  J. Linden,et al.  Indirect effect of guanine nucleotides on antagonist binding to A1 adenosine receptors: occupation of cryptic binding sites by endogenous vesicular adenosine. , 1992, Molecular pharmacology.